Provided herein are lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors, pharmaceutical compositions thereof, and methods of their use for the treatment of disease.
Provided herein are lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors, pharmaceutical compositions of said inhibitors, and methods of their use for the treatment of disease.